NCI SBIR/STTR Supplement Awards
NCI Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) supplement funding opportunities are available for current awardee small businesses. Supplement funding is awarded in addition to project funding to help portfolio companies move forward with commercialization. If you are interested in applying for supplement funding, please reach out to your project officer.
- Notice of Special Interest (NOSI): NCI SBIR Administrative Supplements for Activities to Accelerate the Development and Commercialization of Cancer-Related Innovations (NOT-CA-20-012)
To accelerate the development of promising technologies, NCI announces the opportunity for current NCI-funded SBIR Phase I grantees (R43 grant mechanism only) to seek supplemental project funding via the Administrative Supplement mechanism. The funds from these Administrative Supplements are intended to support research activities that are aimed at:
- achieving next critical milestones in the technology development pathway to make the applicants more competitive for Phase II applications and/or for raising private-sector capital
- accelerating the development of the SBIR product to advance it toward commercialization
- Administrative Supplements to Promote Diversity in Research and Development Small Businesses-SBIR/STTR (Admin Supp Clinical Trial Not Allowed) (PA-21-345)
This administrative supplement opportunity is designed to support research and entrepreneurial experiences for individuals from the identified groups throughout the continuum, from undergraduate to faculty level. Application budgets are limited to no more than the amount of the current parent award, and must reflect the actual needs of the proposed project.
Commercialization Readiness Pilot Program Technical Assistance
- Commercialization Readiness Pilot (CRP) Program Technical Assistance (PAR-20-128)
The Funding Opportunity Announcement (FOA) aims to facilitate the transition of previously funded SBIR and STTR Phase II and Phase IIB projects to the commercialization stage by providing additional support for technical assistance not typically supported through Phase II or Phase IIB grants or contracts. This may include preparation of documents for a submission to the Food and Drug Administration, development of an intellectual property strategy, and/or planning for a clinical trial. Although a significant amount of the work in a CRP award may be subcontracted to other organizations, the small business concern is expected to maintain oversight and management of the research and development throughout the award. Clinical trials not accepted under this FOA.